Indivior Pharmaceuticals, Inc. - 8-K Filing

Indivior accelerates termination of supply agreement with Reckitt Benckiser to January 2027, paying up to $[***] for transition costs (Items: 1.02 Termination of a Material Definitive Agreement, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $INDV

Read the full article at SEC EDGAR

More Regulatory news